As of June 12, 2025, Clearpoint Neuro Inc (CLPT) reports a ROA (Return on Assets) of -48.26%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Clearpoint Neuro Inc's ROA (Return on Assets)
Over recent years, Clearpoint Neuro Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -48.26% |
| 2023-12-31 | -51.78% |
| 2022-12-31 | -29.63% |
| 2021-12-31 | -21.97% |
| 2020-12-31 | -22.97% |
This slight upward trend highlights how Clearpoint Neuro Inc manages its efficiency in using assets to generate earnings over time.
Comparing Clearpoint Neuro Inc's ROA (Return on Assets) to Peers
To better understand Clearpoint Neuro Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Clearpoint Neuro Inc (CLPT) | -48.26% |
| Edwards Lifesciences Corp (EW) | 31.98% |
| IDEXX Laboratories Inc (IDXX) | 26.96% |
| IRadimed Corp (IRMD) | 19.56% |
| Abbott Laboratories (ABT) | 16.46% |
| Resmed Inc (RMD) | 14.86% |
Compared to its competitors, Clearpoint Neuro Inc's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.